Draupnir Bio

Draupnir Bio Plans to Develop a New Type of Cholesterol-Lowering Drug That More Effectively Prevents Heart Thrombosis. The Company Is Developing a Platform for Exploring Glycans to Create Novel Therapies Based on Array Technology, Protein Chemistry, and Advanced Carbohydrate Chemistry. Draupnir Bio Is Capable of Synthesizing, Screening, and Selecting Highly Potent and Specific Heparan Sulfate Mimetic Candidate Drugs for Cardiovascular, Inflammatory, and Infectious Diseases.